European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC

This article was originally published here

“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient care with the approval of LORVIQUA,” said

The post European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply